RECARBRIO (imipenem, cilastin and relebactam)

RECARBRIO (imipenem, cilastin and relebactam) 

OFFICE ADMINISTRATION- IV

Indications:

• Indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

• Indicated in patients 18 years of age and older who have limited or no alternative treatment options for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible gram-negative microorganisms: Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Fusobacterium nucleatum, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Parabacteroides distasonis, and Pseudomonas aeruginosa.

Guidance for the indication(s) above:

• Patient is 18 years of age or older, AND
• Prescribed by or in consultation with infectious disease specialist, AND
• Patient has cUTI or cIAI

Dosing:

• CrCL 90 mL/min or greater: 1.25 grams (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) administered by intravenous (IV) infusion over 30 minutes every 6 hours
• Renally dose adjusted
• The recommended duration of treatment with Recarbrio™ is 4 days to 14 days

Approval: 

• 1 treatment